MEPROGEST 10 MG — DIN 02212072
MEDROXYPROGESTERONE ACETATE : 10 MG · PFIZER CANADA ULC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is MEPROGEST?
MEPROGEST 10 MG contains MEDROXYPROGESTERONE ACETATE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02212072, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 06-Nov-2019. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is MEPROGEST used for?
Hormonal replacement therapy (to oppose estrogen effects on endometrium); functional menstrual disorders due to hormonal imbalance in non-pregnant women.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Medroxyprogesterone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
11 holders have a Canadian DIN containing Medroxyprogesterone, across 38 DINs, of which 7 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AA PHARMA INC | 4 | 4 | AA-MEDROXY | Sourceable in Canada |
| TEVA CANADA LIMITED | 3 | 3 | TEVA-MEDROXYPROGESTERONE | Sourceable in Canada |
| PFIZER CANADA ULC | 9 | 0 | MEPROGEST, PROVERA 100MG TABLETS, PROVERA 10MG TABLETS, PROVERA 2.5MG TABLETS, PROVERA 5MG TABLETS, +2 more | No marketed DIN |
| DOMINION PHARMACAL | 3 | 0 | DOM-MEDROXYPROGESTERONE | No marketed DIN |
| FOURNIER PHARMA INC | 3 | 0 | PROCLIM | No marketed DIN |
| GENPHARM ULC | 3 | 0 | GEN-MEDROXY TABLET 10MG, GEN-MEDROXY TABLET 2.5MG, GEN-MEDROXY TABLET 5MG | No marketed DIN |
| PENTAPHARM LTD. | 3 | 0 | PENTA-MEDROXYPROGESTERONE TABLETS | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-MEDROXYPROGESTERONE | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 3 | 0 | RATIO-MPA | No marketed DIN |
| NU-PHARM INC | 2 | 0 | NU-MEDROXY | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | MEDROXY-2.5, MEDROXY-5 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 100, 500, and 1000 tablets; blister packs of 100. |
| Storage | Store at controlled room temperature 15-30°C. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Medroxyprogesterone |
|---|---|
| ATC code | G03DA02 |
| AHFS class | 68:32.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02212072 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2212072 |
| Brand name | MEPROGEST |
| Generic / active ingredient | MEDROXYPROGESTERONE ACETATE : 10 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | G03DA02 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03DA |
| Current status | CANCELLED PRE MARKET |
| Status date | 06-Nov-2019 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
HRT: 5-10 mg daily for 12-14 days. Secondary amenorrhea/Dysfunctional uterine bleeding: 5-10 mg daily for 10 days beginning on day 16 of cycle.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Thrombophlebitis, thromboembolic disorders, cerebral apoplexy; sensitivity to medroxyprogesterone; undiagnosed vaginal/urinary bleeding; cancer of breast or genital organs; pregnancy.
Warnings and precautions
Alert for thrombotic disorders; discontinue if sudden vision loss occurs. High doses may cause corticoid-like activity/cushingoid symptoms. Anaphylactic reactions reported.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
7 of 38 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-MEDROXY | 100 MG | TABLET | AA PHARMA INC | MARKETED | 02267640 |
| AA-MEDROXY | 2.5 MG | TABLET | AA PHARMA INC | MARKETED | 02244726 |
| AA-MEDROXY | 5 MG | TABLET | AA PHARMA INC | MARKETED | 02244727 |
| AA-MEDROXY | 10 MG | TABLET | AA PHARMA INC | MARKETED | 02277298 |
| TEVA-MEDROXYPROGESTERONE | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02221306 |
| TEVA-MEDROXYPROGESTERONE | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02221292 |
| TEVA-MEDROXYPROGESTERONE | 2.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02221284 |
| DOM-MEDROXYPROGESTERONE | 5 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | 02247582 |
| DOM-MEDROXYPROGESTERONE | 2.5 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | 02247581 |
| DOM-MEDROXYPROGESTERONE | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | 02247583 |
2 · Same class — other molecules in ATC G03DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Progesterone | ACT PROGESTERONE INJECTION · AURO-PROGESTERONE · CRINONE · ENDOMETRIN · +12 more | 17 | 9 | Yes |
| Medroxyprogesterone | AA-MEDROXY · DOM-MEDROXYPROGESTERONE · GEN-MEDROXY TABLET 10MG · GEN-MEDROXY TABLET 2.5MG · +16 more | 38 | 7 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03DB | Dienogest · Medrogestone | 7 | 5 |
| G03DC | Norethisterone | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MEPROGEST called?
The same molecule, Medroxyprogesterone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Depo-Provera | Latin | Norway |
| Provera | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Medroxyprogesterone called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Medroxyprogesterone, published to help those searches reach this page.
| Language | Medroxyprogesterone |
|---|---|
| Chinese (Simplified) 简体中文 | 醋酸甲羟孕酮 |
| Russian Русский | Медроксипрогестерон |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.